The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy

HIV Medicine

Volumn 10, Issue 8, 2009, Pages 477-481

  Palmisano, L ^a   Giuliano, M ^a   Galluzzo, C M ^a   Amici, R ^a   Andreotti, M ^a   Weimer, L E ^a   Pirillo, M F ^a   Fragola, V ^a   Bucciardini, R ^a   Vella, S ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

HAART; HIV 1DNA; Mutations; Treatment interruptions

Indexed keywords

LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; POPULATION RESEARCH; PRIORITY JOURNAL; RESISTANCE ASSOCIATED MUTATION; TREATMENT DURATION; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; ITALY; MALE; MIDDLE AGED; MUTATION; PROVIRUSES; RNA, VIRAL; TIME FACTORS; YOUNG ADULT;

EID: 68449103566     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00715.x     Document Type: Article

References (15)

1. El-Sadr WM, Lundgren JD, Neaton JD et al. Strategies for management of antiretroviral therapy (SMART) study group. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
2. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1-128. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf (Accessed August 30, 2008)
3. Arnedo-Valero M, Garcia F, Gil C et al. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin Infect Dis 2005; 41: 883-890.
4. Ruiz L, Paredes R, Gomez G et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2007; 21: 169-178.
5. Marchou B, Tangre P, Charreau I et al. Intermittent antiretroviral therapy in patients with controlled HIV infection. AIDS 2007; 21: 457-466.
6. Palmisano L, Giuliano M, Bucciardini R et al. Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: The Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) Study. J Acquir Immune Defic Syndr 2007; 46: 39-47.
7. Diaz RS, Accetturi CA, Sucupira MC. Emergence of resistance mutations preceding virologic failure in patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49: 111-113.
8. Ghosn J, Pellegrin I, Goujard C et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006; 20: 159-170.
9. Parisi SG, Mazzi R, Boldrin C et al. Drug-resistance mutations can be archived very early in HIV primary infection. AIDS 2006; 20: 1337-1338.
10. Opravil M, Hirschel B, Lazzarin A et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251-1260.
11. Pellegrin I, Caumont A, Garrigue I et al. Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. J Infect Dis 2003; 187: 38-46.
12. Izopet J, Cazabat M, Pasquier C et al. Evolution of total and integrated HIV-q DNA and change in DNA sequences in patients with sustained plasma virus suppression. Virology 2002; 302: 329-404.
13. Izopet J, Marchou B, Charreau I et al. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4 T-cell counts and antiviral response. Antivir Ther 2008; 13: 537-545.
14. Martinez-Picado J, Frost SDW, Izquierdo N et al. Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals. J Virol 2002; 76: 12344-12348.
15. Palmisano L, Giuliano M, Chiarotti F et al. Modifications of HIV-1 DNA and provirus-infected cells during 24 months of intermittent highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 48: 68-71.